China Medical System Holdings Ltd

The company maintains a strong liquidity position, with a current ratio of 6.33, indicating a significant buffer of current assets over current liabilities. Free cash flow of CNY 535.24 million and operating cash flow of CNY 758.42 million support operational flexibility. However, the firm holds CNY 690.08 million in long-term debt, and net cash is negative after subtracting total debt, signaling potential liquidity risk. Profitability metrics show a return on equity (ROE) of 8.56% and return on assets (ROA) of 7.76%, both above the typical thresholds for pharmaceutical firms. Gross profit of CNY 5.87 billion and operating income of CNY 1.88 billion reflect strong cost control and pricing power. The debt-to-equity ratio of 0.04 suggests a conservative capital structure, with minimal leverage risk. Geographic and segment exposure is concentrated in China, with no disclosed international operations or segment breakdowns in the latest financials. Revenue of CNY 8.21 billion is derived primarily from pharmaceutical sales, with no material diversification across product lines or regions. Growth trajectory remains stable, with no explicit guidance provided for the current or next fiscal year. Analysts project a mean price target of CNY 17.46, with a median of CNY 17.50, and a mean recommendation of 1.88 (leaning toward buy). The firm has not disclosed capital expenditure plans beyond the CNY 514.41 million outflow in the latest period. Risk factors include liquidity constraints due to negative net cash and the absence of a detailed segment breakdown, which limits visibility into product-specific performance. Dilution risk is assessed as low, with no recent share issuance or ATM/shelf disclosures reported. Recent filings and transcripts are not available in the provided data, but the firm’s financials suggest a stable, low-growth profile with strong cash generation and conservative leverage. Analysts remain cautiously optimistic, with six buy and two strong-buy ratings.